All In Biotech

Drug Trial Radar · NCT07933848

A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment

A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF PRIFETRASTAT IN PARTICIPANTS WITH MODERATE AND SEVERE RENAL IMPAIRMENT RELATIVE TO PARTICIPANTS WITH NORMAL RENAL FUNCTION.

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Nov 17, 2026

Primary completion

May 21, 2028

Study completion May 27, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function. This study is seeking participants who: * Have moderate or severe renal impairment or * Healthy people with normal kidney function All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function. Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.

Conditions

  • Renal Impairment
  • Healthy Adults

Interventions

  • PrifetrastatDrug

    Prifetrastat administered by mouth as a single dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of PrifetrastatTime frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
  2. Maximum Observed Plasma Concentration (Cmax) of PrifetrastatTime frame: Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Floridian Clinical Research

    Miami Lakes, Florida

  • Genesis Clinical Research, LLC

    Tampa, Florida

  • Nucleus Network Minneapolis

    Saint Paul, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.